"Capillary Network" Strategy Lights Up New Course for Innovative Drugs Going Global

Click the blue text to follow us!

On December 8, 2025, the 2025 T-EDGE Annual Conference hosted by TMTPost Group kicked off in Beijing. The roundtable forum themed “China’s Innovative Drugs Going Global: The Evolution from ‘Borrowing Ships’ to ‘Building Own Vessels’” brought together top industry leaders. Mr. Wildman Liu Weimin, Vice President of Stellar Biotech, was invited to participate, sharing on-the-ground experience alongside representatives from industry leaders including 3SBio and Sinopharm Group. His “Capillary Network” globalization strategy struck a chord across the audience, injecting pragmatic new momentum into the sector.

Today, China’s innovative drug sector is moving from sporadic exploration to a critical phase of scaled expansion. From early license-out models to multi-billion-dollar strategic collaborations, Chinese pharma enterprises are rapidly evolving from "participants" to "drivers" of global pharmaceutical innovation. The debate between "borrowing ships" and "building vessels" has become a core industry topic.

Mr. Liu emphasized that this is not an either-or choice, but a strategic application question tailored to each company’s resources and development stage. The core of going global is the hard capability to deliver high-quality medicines to global patients efficiently and safely.

While leading pharma enterprises can “build vessels” or “borrow ships” with capital advantages, a vast number of small and medium-sized innovative biotech firms struggle with tight cash flow, limited overseas resources, and insufficient global capabilities. Many high-quality products face intense domestic competition yet lack channels to go global.

With keen insight into these pain points, Stellar Biotech has taken a differentiated path focused on deep regional penetration and pragmatic commercialization, creating the unique “Capillary Network” globalization model.

Mr. Liu stated clearly that the unmet medical demand in Southeast Asia, Hong Kong and Macao is the key to breaking through. By targeting this supply-demand mismatch, Stellar Biotech has built a full-chain service system covering accelerated product access and early market entry. Through flexible pathways including the Southeast Asia NPP model and fast-track access in Hong Kong and Macao, the company helps enterprises achieve phased revenue during the registration cycle, enabling “small steps, fast runs, and quick cash recovery” — laying a solid foundation for entering major global markets.

Looking ahead, Mr. Liu and fellow panelists agreed that sustained innovation, healthy cash flow, and ecosystem collaboration are the core competitive strengths for going global. Biomedical enterprises are shifting from “going alone” to “win-win cooperation”. With technological advances such as AI-powered drug discovery, the globalization of Chinese pharmaceutical products is poised for explosive growth.

Stellar Biotech will uphold the DNA of pragmatism, deep cultivation, and collaboration, continuously optimize its full-chain service capabilities, and make its “Capillary Network” even more efficient and far-reaching.

Stellar Biotech’s appearance at the 2025 T‑EDGE Summit reflects strong industry recognition of its differentiated practices. As an innovative service company focused on the cross‑regional commercialization of global pharmaceuticals and medical devices, Stellar Biotech will act as a trusted partner to guide more Chinese pharma enterprises through the challenges of going global, deliver China’s innovative achievements to patients worldwide, and write a remarkable chapter in the globalization of China’s innovative drugs.

Stellar Biotech is an innovative pharmaceutical and medical device service company dedicated to the cross-regional introduction, R&D, manufacturing, and commercialization of global pharmaceuticals and medical devices. The company specializes in accelerated market access for global pharma and medtech enterprises, providing end-to-end support for innovative drugs, proprietary Chinese medicines, and advanced medical devices in Southeast Asia (including Hong Kong and Macao) — including regulatory registration, licensing, early market access, drug distribution, and marketing promotion — helping patients gain faster access to world-class advanced medical resources.

Backed by more than 30 medical KOLs and industry experts, Stellar Biotech currently has over 10 commercialization projects underway covering innovative drugs, proprietary Chinese medicines and medical devices, with an expected total product market scale exceeding ¥5 billion.

This is a polished, formal, industry-standard English press release that you can use directly on your official website, PPTs, LinkedIn, and global marketing materials.